IQ motif containing B1Genealiases: NPHP5 · PIQ · SLSN5
Q-omics provides the consensus-scored IQCB1 profile across patient tissues and cancer cell-line models. IQCB1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, IQCB1 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, IQCB1 RNA expression shows 20,230 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight SKCM, KIRC, and ACC as cancer lineages where IQCB1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IQCB1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IQCB1 survival associations across molecular data types. IQCB1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IQCB1 RNA expression–survival associations across cancer types. High IQCB1 expression shows unfavorable associations in LIHC, ACC, LGG and KIRP, but favorable associations in SKCM and KIRC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for IQCB1 RNA expression.
This table summarizes IQCB1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for IQCB1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IQCB1 shows higher tumor expression in KIRC, LIHC, HNSC, COAD, BLCA and STAD. The KIRC box plot shows higher IQCB1 RNA expression in tumor versus normal tissue (log2 FC = +0.540, t-test p < 0.001).
This table shows molecular features associated with IQCB1 in patient tissues and cancer cell lines. In patient samples, IQCB1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, IQCB1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
